NCT01256580

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Massachusetts Eye and Ear Infirmary · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV) due to other causes. The limitation of this type of treatment is the necessity for frequent intraocular injections. The purpose of this study is to determine if using anti-VEGF therapy in combination with photodynamic therapy can reduce the number of treatments needed with monotherapy while achieving similar visual results. There are ongoing multicenter trials evaluating combination therapy in patients with wet AMD but no similar trial for patients with CNV due to non-AMD causes. Therefore, in this study the investigators will focus on patients with CNV not due to AMD.

Conditions

• Choroidal Neovascularization
• Myopia
• Punctate Inner Choroidopathy (PIC)
• Multifocal Choroiditis
• Ocular Histoplasmosis Syndrome
• Central Serous Chorioretinopathy (CSC)
• Angioid Streaks
• Trauma, or Hereditary Eye Diseases

Interventions

Type	Name	Description
DRUG	Bevacizumab (Avastin; Genentech, Inc.)	1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
DRUG	Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy	Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone

Timeline

• Start date: 2010-08-01
• Primary completion: 2013-03-01
• Completion: 2013-09-01
• First posted: 2010-12-08
• Last updated: 2014-01-14